Inhibitors of intracellular chloride regulation induces cisplatin resistance canine osteosarcoma cells

In Vivo

Volumn 13, Issue 5, 1999, Pages 375-383

  Yarbrough, Jason W ^a   Merryman, Joyce I ^a   Barnhill, Mary Ann ^a   Hahn, Kevin A ^a  

^a UNIVERSITY OF TENNESSEE   (United States)

Author keywords

Anticancer resistance; Canine; Cisplatin; Ion transport inhibitors; Osteosarcoma; pH

Indexed keywords

4 ACETAMIDO 4' ISOTHIOCYANATOSTILBENE 2,2' DISULFONIC ACID; ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); ADENOSINE TRIPHOSPHATASE INHIBITOR; AMILORIDE; ANTINEOPLASTIC AGENT; BICARBONATE; CHLORIDE ION; CISPLATIN;

ANIMAL CELL; ARTICLE; CELL LEVEL; CELL PH; CELL SURVIVAL; CONTROLLED STUDY; CULTURE MEDIUM; DOG; DRUG ACCUMULATION; DRUG RESISTANCE; ION TRANSPORT; NONHUMAN; OSTEOSARCOMA CELL;

EID: 0033392582     PISSN: 0258851X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Hahn KA, Bravo L, Adams WH, and Frazier DL: Naturally occurring tumors in dogs as comparative models for cancer therapy research. In Vivo 8: 133-144, 1994.
2. Hahn KA, Frazier DL, Hoopes PJ, and Legendre AM: Plasma platinum levels are inversely related with efficacy: implications for dosing cisplatin in dogs. Proc Vet Cancer Soc (b): 106, 1997.
3. Hahn KA, Hurd C and Cantwell HD: Single phase methylene diphosphate bone scintigraphy in the diagnostic evaluation of dogs with osteosarcoma. J Am Vet Med Assoc. 196: 1483-1486, 1990.
4. Hahn KA, Legendre AM, and Talbott JA: The frequency of micronuclei in lymphocytes of dogs with osteosarcoma - a predictive variable for tumor response during cisplatin chemotherapy. Cancer Epidem Biomarkers Prevention 5: 653-656, 1996.
5. Hahn KA, Legendre AM, Schuller HM: Amputation and dexniguldipine as treatment for canine appendicular osteosarcoma. J Cancer Res Clin Oncol 123: 34-38, 1997.
6. Knapp DW, Richardson RC, Bonney PL, and Hahn KA: Cisplatin therapy in 41 dogs with malignant tumors. J Vet Int Medicine 2: 41-46, 1988.
7. Shoieb AM, Hahn KA, van Laack RL, Barnhill MA: In vitro reversal of glutathione-S-transferase-mediated resistance in canine osteosarcoma (COS31) cells. In Vivo 12: 455-462, 1998.
8. Shoieb AM, Hahn KA. An in vitro/in vivo experimental model system for the study of human osteosarcoma: canine osteosarcoma cells (COS31) which retain osteoblastic and metastatic properties in nude mice. In Vivo 12: 463-472, 1998.
9. Shoieb AS, Hahn KA: Detection and significance of glutathione-S-transferase π in osteogenic tumors of dogs. Intl J Oncology 10: 635-639, 1997.
10. Gosland M, Lum B, Schimmelpfennig J, Baker J, and Doukas M: Insights into mechanisms of cisplatin resistance and potential for its clinical reversal. Pharmacotherapy 16: 16-39, 1996.
11. Zwelling LA, and Kohn KW: Effects of cisplatin on DNA and the possible relationships to cytotoxicity and mutagenicity in mammalian cells. In: Cisplatin: Current Status and New Developments. Prestayko A, Crooke S, Carter S (eds). New York: Academic Press pp: 21-37, 1980.
12. +-adenosine triphosphate in the accumulation of cis-diamminedichloro-platinum(II)-resistant and -sensitive L1210 cells. Cancer Res 47: 519-522, 1987.
13. Jennerwein M, Andrews PA: Effect on intracellular chloride on the cellular pharmacodynamics of cis-diamminedichloroplatinum(II). Drug Metab Disp 23: 178-184, 1995.
14. Laurencot CM, Andrews PA, Kennedy KA: Inhibitors of intracellular pH regulation induce cisplatin resistance in EMT6 mouse mammary tumor cells. Oncology Res 7: 363-369, 1995.
15. Laurencot CM, Kennedy KA: The effect of low pH on the cytotoxicity of cisplatin in EMT6 mammary tumor cells. Oncology Res 7: 371-380, 1995.
16. Reishus JD, Martin DS Jr: cis-Dichlorodiammine-platinum(II). Acid hydrolysis and isotopic exchange of the chloride ligands. J Am Chem Soc 83: 2457-2462, 1961.
17. Vaupel P, Kallinowski F, Okunieff P: Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. Cancer Res 49: 6449-6465, 1989.
18. Kennedy KA: Hepoxic cells as specific drug targets for chemotherapy. Anti-Cancer Drug Des 2: 181-194, 1987.
19. Atema A, Buurman KJH, Noteboom H, and Smets LA: Potetiation of DNA-adduct formation and cytotoxicity of platinum containing drugs by low pH. Int J Cancer 54: 166-172, 1993.
20. Yamagata M and Tannock IF: The chronic administration of drugs that inhibit the regulation of intracellular pH: In vitro and anti-tumor effects.
21. Wike-Hooley JL, Haveman J, Reinhold JS: The relevance of tumor pH to the treatment of malignant disease. Radiother Oncol 2: 343-366, 1984.
22. Lee AH and Tannock IF: Heterogeneity of Intracellular pH and mechanisms that regulate intracellular pH in populations of cultured cells. Cancer Res 58: 1901-1908, 1998.
23. Boyer MJ, Tannock IF: Regulation of intracellular pH in tumor cell lines: Influences of microenvironmental conditions. Cancer Res 52: 4441-4447, 1992.
24. Gerweck IE, Rhee JG, Koutcher JA, Song CW and Urano M: Regulation of pH in murine tumor and muscle. Radiat Res 126: 206-209, 1991.
25. - by stimulating three acid base transport systems. Nature (London) 337: 648-651, 1989.
26. Tonnessen TI, Ludt J, Sandvig K, and Olsnes S: Bicarbonate/chloride antiport in Vero cells: 1. Evidence for both sodium-linked and sodium-independent exchange. J Cell Physiol 132: 183-191, 1987.
27. Roos A, Boron WF: Intacellular pH. Physiol Rev 61: 296-434, 1981.
28. - antiporter. Cell 56: 271-280, 1989.
29. + exchange system. Mol Pharmacol 25: 131-136, 1983.
30. Kottgen M, Leipziger J, Fischer KG, Nitschke R and Greger R: pH regulation in HT29 colon carcinoma cells. Pflugers Archiv 428: 179-185, 1994.
31. - exchange systems in Chinese hamster lung fibroblasts. J Biol Chem 263: 6122-6127, 1988.
32. + exchange and growth factor-induced cytosolic pH changes. Role in cellular proliferation. Biochim Biophys Acta 988: 73-97, 1989.
33. Rotin D, Robinson B, Tannock IF: Influence of hypoxia and an acidic environment on the metabolism and viability of cultured cells: potential implications for cell death in tumors. Cancer Res 46: 2821-2826, 1986.
34. Awasthi S, Sharma R, Singhal SS, Herzog NK, Chaubey M, and Awasthi YC: Modulation of cisplatin cytotoxicity by sulphasalazine. Br J Cancer 70: 190-4, 1994.
35. Miller SE, House DA: The hydrolysis products of cis-dichlorodiammineplatinum (II) 3. Hydrolysis kinetics at physiological pH. Inorganica Chim Acta 173: 53-60, 1990.
36. Rosen G, Forscher CA, Mankin HJ, and Selch MT: Bone Tumors. In: Holland JF, Bast RC, Morton DL, Frei E, Kufe DW, and Weichselbaum RR, eds. Cancer Medicine, 4th Edition. Philadelphia: Williams & Wilkins Co., pp:2503-2558, 1997.
37. Speelmans G, Sips WHHM, Grisel RJH, Staffhorst RWHM, Fichtinger-Schepman AMJ, Reedijk J, Krijff B: The interaction of the anti-cancer drug cisplatin with phospholipids is specific for negatively charged phospholipids and takes place at low chloride ion concentration. Biochim Biophys Acta 1283: 60-66, 1996.
38. Steel RGD, Torrie JH: Observations. In: Steel RGD and Torrie JH, eds. Principles and Procedures of Statistics. New York, NY: McGraw-Hill, 1980, pp:8-38, 1980.